BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Viamet Pharmaceuticals 

406 Blackwell Street
Suite 200
Durham  North Carolina  27701-3984  U.S.A.
Phone: 919-969-7505 Fax: n/a


SEARCH JOBS




Industry
Pharmaceutical

Segment
Start Up





 Company News
Viamet Pharmaceuticals Withdraws $75 Million IPO, Spins Off Cancer Program To Form Innocrin Pharmaceuticals 10/22/2014 6:15:45 AM
Viamet Pharmaceuticals Reels In $60 Million Series D Financing 10/21/2014 5:38:42 AM
Viamet Pharmaceuticals Receives Orphan Drug Designation For VT-1129 9/11/2014 10:11:08 AM
Viamet Pharmaceuticals Announces Appointment Of Amir Tavakkol, Ph.D., As Chief Development Officer 7/22/2014 10:24:59 AM
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Studies Of VT-1161 With Moderate To Severe Interdigital Tinea Pedis 7/11/2014 11:04:25 AM
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Study Of VT-1161 In Patients With Moderate To Severe Acute Vulvovaginal Candidiasis 7/11/2014 9:20:05 AM
Durham Drug Developer Viamet Pharmaceuticals Files For $75 Million IPO 7/8/2014 7:22:35 AM
Viamet Pharmaceuticals Reports Positive Interim Results Of Phase 2 Interdigital Tinea Pedis Study Of VT-1161 3/12/2014 8:16:59 AM
Viamet Pharmaceuticals Reports Positive Interim Results Of Phase 2 Study Of VT-1161 2/19/2014 7:20:49 AM
Viamet Pharmaceuticals To Present At The 32nd Annual J.P. Morgan Healthcare Conference 1/8/2014 10:38:05 AM
123